Stock of Cytokinetics, Incorporated (CYTK) tumbled 14 percent on Thursday after rumoured deal fail to reach a conclusion.
Currently, Cytokinetics stock is dropping 14.44 percent, to $86.96 from a previous close of $101.63 on a volume of 9,465,031. It traded in range of $25.98 to $110.25 in the past 52-weeks.
Last week the company's stock boomed over rumours of deal with Novartis. However, Novartis CEO clarified that the firm is only focusing on deals below $5 billion, following which Cytokinetics stock started to plummet.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.